Fig. 1
From: Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19
Flow diagram of the design. According to the predefined inclusion and exclusion criteria, we performed a 2:1 propensity score matching analysis and obtained clinical data from 397 patients who received azvudine and 199 patients who received Paxlovid for therapeutic intervention.
